← All trials
NCT04316013
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2025
- First posted
- Mar 20, 2020
- Last posted
- Mar 20, 2020
- Enrollment
- 5736
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peter MacCallum Cancer CentreLead sponsor
- Peter MacCallum Cancer CentreOverall official - principal investigator
- Government of AustraliaCollaborator
- Australian and New Zealand College of AnaesthetistsCollaborator
- University of MelbourneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.